Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Interferon beta-1a - Biogen

Drug Profile

Interferon beta-1a - Biogen

Alternative Names: Avonex; Avonex Pen; IFN-b-1a; Interferon β-1a

Latest Information Update: 01 Apr 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biogen Idec
  • Developer Biogen; Eisai Co Ltd; Merck & Co; Nektar Therapeutics
  • Class Antiasthmatics; Antineoplastics; Antivirals; Interferons; Vascular disorder therapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple sclerosis
  • Discontinued Chronic inflammatory demyelinating polyradiculoneuropathy; Glioma; Hepatitis B; Hepatitis C; Human papillomavirus infections; Pulmonary fibrosis; Ulcerative colitis

Most Recent Events

  • 01 Apr 2021 No development reported - Phase-II for Multiple sclerosis (Adjunctive treatment) in Italy (SC) (Biogen pipeline, April 2021)
  • 06 Feb 2020 Merck KGaA terminates the phase II INCREASE trial in Multiple sclerosis (Adjunctive treatment) in Italy due to slow recruitment (SC) (NCT03387046)
  • 11 Jan 2019 Merck KGaA completes the phase-II INCREASE trial in Multiple sclerosis in Italy (NCT03387046)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top